Page last updated: 2024-11-01

ofloxacin and Chronic Illness

ofloxacin has been researched along with Chronic Illness in 156 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Research Excerpts

ExcerptRelevanceReference
"5% levofloxacin, with and without eyelid scrub, in patients with chronic blepharoconjunctivitis (CBC)."9.14A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. ( He, L; Kampik, A; Kreutzer, TC; Mino de Kaspar, H; Nentwich, MM; Ta, CN; Yactayo-Miranda, Y, 2009)
"The aim of this study was to confirm further the efficacy and safety of levofloxacin in patients with chronic bacterial prostatitis (CBP) in Europe."9.13Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. ( Botto, H; Naber, KG; Roscher, K; Schaefer, V, 2008)
"To evaluate the clinical efficacy of the Chinese medicine Yiqigushen Capsule combined with levofloxacin on type III A prostatitis."9.13[Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis]. ( Guo, DF; Wang, HP; Zhang, HZ, 2008)
"Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily."9.12Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. ( Barbone, F; De Maria, M; Giannarini, G; Manassero, F; Mogorovich, A; Morelli, G; Selli, C; Valent, F, 2007)
"To study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis."9.12[Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis]. ( Cai, X; Huang, YF; Shang, XJ; Teng, WH; Xu, H, 2007)
"This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg QD for 5 days or amoxicillin/clavulanate 875 mg/125 mg BID for 10 days."9.12Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. ( Ambrusz, ME; Fisher, AC; Grossman, RF; Kahn, JB; Khashab, MM, 2006)
"We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin."9.11Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005)
"To demonstrate that 5 days of treatment with a new fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with levofloxacin in adult patients with acute exacerbation of chronic bronchitis (AECB)."9.11A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Fogarty, C; Fulambarker, A; Sethi, S, 2004)
"To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis."9.10Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003)
"To perform a Canadian multicenter randomized placebo-controlled trial to evaluate the safety and efficacy of 6 weeks of levofloxacin therapy compared with placebo in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."9.10Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. ( Barkin, J; Brock, G; Casey, RW; Clark, J; Downey, J; Flax, S; Goldfarb, B; Nickel, JC; Palmer, BW; Patrick, AB; Pommerville, PJ; Steinhoff, G; Zadra, J, 2003)
"A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil."9.09Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999)
"We conducted a prospective, randomized, open-label trial, comparing oral ofloxacin with intravenous imipenem-cilastatin for the treatment of chronic osteomyelitis in order to evaluate the efficacy and tolerance."9.09Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. ( Barberán, J; Borja, J; García-Barbal, J; Gomis, M; Khorrami, S; Sánchez, B, 1999)
"The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed."9.09Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. ( Greenberg, RN; Newman, MT; Pectol, RW; Shariaty, S, 2000)
"The objective of this randomized, double-blind study was to compare the clinical efficacy of levofloxacin at two different dosages with that of cefuroxime axetil in patients with acute purulent exacerbations of chronic bronchitis and, in particular, to assess the impact of the susceptibility to levofloxacin on the clinical findings."9.09Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. ( Davies, BI; Maesen, FP, 1999)
"Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)."9.08Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998)
"In a double-blind study of 137 patients with exacerbation of chronic bronchitis and chronic obstructive lung disease, the efficacy and safety of ofloxacin was compared with that of trimethoprim-sulfamethoxazole (TMP/SMX)."9.07Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. ( Boye, NP; Gaustad, P, 1991)
"128 Patients (45 female, 83 male) with acute exacerbations of chronic bronchitis were treated with either cefuroxime axetil 2 x 500 mg/d (n = 65) or ofloxacin 2 x 200 mg/d for 7-8 days in a randomized controlled multicenter trial."9.07[Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin]. ( Kleckow, M, 1991)
"A multicentric study was conducted to evaluate the clinical efficacy and tolerance of ofloxacin in the treatment of chronic sinusitis and chronic otitis (CSOM) in outpatients."9.07Effectiveness and safety of ofloxacin in chronic otitis media and chronic sinusitis in adult outpatients. ( Cohen, B; Gehanno, P, 1993)
"The present study compared ofloxacin and erythromycin in a double-blind study with parallel groups for clinical efficacy and the number and severity of adverse reactions in patients treated in general practice for acute or chronic sinusitis."9.07Antibiotic treatment of sinusitis in general practice. A double-blind study comparing ofloxacin and erythromycin. ( Egede, F; Husfeldt, P; Nielsen, PB, 1993)
"The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections."9.06An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987)
"In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b."9.06[Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986)
"In a double-blind study in 84 patients with chronic bronchitis and purulent exacerbations, ofloxacin 200 mg b."9.06A comparative study of ofloxacin and pivmecillinam in acute exacerbations of chronic bronchitis. ( Egede, F; Kristensen, I, 1990)
"The efficacy and safety of ofloxacin 400 mg once daily and amoxycillin/clavulanic acid 500/125 mg three times daily were compared in a double-blind manner in patients with an acute exacerbation of chronic bronchitis."9.06A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis. ( Beumer, HM; Hoepelman, IM; Möllers, MJ; Overbeek, BP; Rademaker, CM; Rozenberg-Arska, M; Sips, AP; Verhoef, J, 1990)
"192 patients, most of them ambulatory, with acute exacerbation of chronic bronchitis were treated with 10- to 14-day courses of oral ofloxacin receiving 400 mg once daily or doxycycline first 200 mg and then 100 mg once daily in this randomized observer-blinded multicentre study."9.06Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis. ( Ammälä, K; Aro, A; Backman, R; Keistinen, T; Lehtipuu, AL; Punakivi, L; Saarelainen, P; Veneskoski, T; Vilkka, V, 1990)
"The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices."7.77[Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011)
"Studies of acute exacerbations of chronic bronchitis (EXCB) included in the approval documents of levofloxacin (LVF) were reviewed in light of the good conditions of use defined by the French marketing approval and the AFSSAPS recommendations."7.72[Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors]. ( Brumpt, I; Veyssier, P; Zuck, P, 2004)
"Two different oral ofloxacin regimens, a daily single-dose regimen with 200 mg (Regimen I) and an every-two-week multidose regimen with 3 x 200 mg/day (Regimen II) was compared as to the efficacy in controlling repeated acute exacerbations of chronic respiratory tract infections."7.69Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections. ( Motomiya, M; Nukiwa, T; Oizumi, K; Watanabe, A, 1995)
"The clinical efficacy and the safety of ofloxacin in lower respiratory tract infections were evaluated by 42 research groups in Japan."7.67Clinical evaluation of ofloxacin in lower respiratory tract infections. ( Kobayashi, H, 1986)
"After ascertaining the bacterial spectrum in 210 patients with Otitis media acuta, Otitis media chronica mesotympanalis and Otitis media chronica epitympanalis, the clinical efficacy of oral therapy with ofloxacin in 40 patients from each of these groups was assessed."7.67Ofloxacin in oral chemotherapy of acute and chronic otitis media. ( Lenarz, T, 1986)
"After ascertaining the bacterial spectrum in 105 patients with Otitis media acutissima, Otitis media chronica mesotympanalis and Otitis media chronica epitympanalis, the efficacy of oral therapy with ofloxacin in five patients from each of these groups was assessed."7.67[Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences]. ( Lenarz, T, 1986)
"Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml."5.36In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010)
"Levofloxacin was given to each patient at a dose of 300 mg or 400 mg a day for 7-14 days (average 12."5.28[Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis]. ( Horiba, M; Suzuki, K, 1992)
"We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0."5.16[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction]. ( Chao, WF; Huang, XK; Liang, P; Liu, JW; Wang, L; Wang, QT; Yang, H; Yang, W; Zhou, P, 2012)
"5% levofloxacin, with and without eyelid scrub, in patients with chronic blepharoconjunctivitis (CBC)."5.14A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. ( He, L; Kampik, A; Kreutzer, TC; Mino de Kaspar, H; Nentwich, MM; Ta, CN; Yactayo-Miranda, Y, 2009)
"To evaluate the clinical efficacy of the Chinese medicine Yiqigushen Capsule combined with levofloxacin on type III A prostatitis."5.13[Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis]. ( Guo, DF; Wang, HP; Zhang, HZ, 2008)
"The aim of this study was to confirm further the efficacy and safety of levofloxacin in patients with chronic bacterial prostatitis (CBP) in Europe."5.13Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. ( Botto, H; Naber, KG; Roscher, K; Schaefer, V, 2008)
"This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg QD for 5 days or amoxicillin/clavulanate 875 mg/125 mg BID for 10 days."5.12Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. ( Ambrusz, ME; Fisher, AC; Grossman, RF; Kahn, JB; Khashab, MM, 2006)
"To study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis."5.12[Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis]. ( Cai, X; Huang, YF; Shang, XJ; Teng, WH; Xu, H, 2007)
"Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily."5.12Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. ( Barbone, F; De Maria, M; Giannarini, G; Manassero, F; Mogorovich, A; Morelli, G; Selli, C; Valent, F, 2007)
"We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin."5.11Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005)
"To demonstrate that 5 days of treatment with a new fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with levofloxacin in adult patients with acute exacerbation of chronic bronchitis (AECB)."5.11A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Fogarty, C; Fulambarker, A; Sethi, S, 2004)
"To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis."5.10Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003)
"To perform a Canadian multicenter randomized placebo-controlled trial to evaluate the safety and efficacy of 6 weeks of levofloxacin therapy compared with placebo in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."5.10Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. ( Barkin, J; Brock, G; Casey, RW; Clark, J; Downey, J; Flax, S; Goldfarb, B; Nickel, JC; Palmer, BW; Patrick, AB; Pommerville, PJ; Steinhoff, G; Zadra, J, 2003)
"The objective of this randomized, double-blind study was to compare the clinical efficacy of levofloxacin at two different dosages with that of cefuroxime axetil in patients with acute purulent exacerbations of chronic bronchitis and, in particular, to assess the impact of the susceptibility to levofloxacin on the clinical findings."5.09Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. ( Davies, BI; Maesen, FP, 1999)
"We conducted a prospective, randomized, open-label trial, comparing oral ofloxacin with intravenous imipenem-cilastatin for the treatment of chronic osteomyelitis in order to evaluate the efficacy and tolerance."5.09Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. ( Barberán, J; Borja, J; García-Barbal, J; Gomis, M; Khorrami, S; Sánchez, B, 1999)
"The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed."5.09Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. ( Greenberg, RN; Newman, MT; Pectol, RW; Shariaty, S, 2000)
"A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil."5.09Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999)
"Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)."5.08Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998)
"Fifteen patients with various forms of pyelonephritis and chronic cystitis were treated with ofloxacin."5.08[Comprehensive treatment with ofloxacin in pyo-inflammatory urologic diseases]. ( Pytel', IuA; Volkova, VS, 1996)
"Ofloxacin was used in the treatment of 15 patients (12 with pneumonia and 3 with aggravated chronic bronchitis)."5.08[Stepdown ofloxacin therapy in bronchopulmonary diseases]. ( Lenkova, NI; Makarova, OV; Nonikov, VE; Ritchik, LA, 1996)
"A multicentric study was conducted to evaluate the clinical efficacy and tolerance of ofloxacin in the treatment of chronic sinusitis and chronic otitis (CSOM) in outpatients."5.07Effectiveness and safety of ofloxacin in chronic otitis media and chronic sinusitis in adult outpatients. ( Cohen, B; Gehanno, P, 1993)
"Two different oral ofloxacin regimens, daily single-dose treatment with 200 mg (Regimen I) and every two week multidose treatment with 3 x 200 mg/day (Regimen II), were compared to evaluate the efficacy of quinolone regimens in controlling acute exacerbations of chronic respiratory tract infections."5.07Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. ( Watanabe, A, 1991)
"In a double-blind study of 137 patients with exacerbation of chronic bronchitis and chronic obstructive lung disease, the efficacy and safety of ofloxacin was compared with that of trimethoprim-sulfamethoxazole (TMP/SMX)."5.07Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. ( Boye, NP; Gaustad, P, 1991)
"The present study compared ofloxacin and erythromycin in a double-blind study with parallel groups for clinical efficacy and the number and severity of adverse reactions in patients treated in general practice for acute or chronic sinusitis."5.07Antibiotic treatment of sinusitis in general practice. A double-blind study comparing ofloxacin and erythromycin. ( Egede, F; Husfeldt, P; Nielsen, PB, 1993)
"128 Patients (45 female, 83 male) with acute exacerbations of chronic bronchitis were treated with either cefuroxime axetil 2 x 500 mg/d (n = 65) or ofloxacin 2 x 200 mg/d for 7-8 days in a randomized controlled multicenter trial."5.07[Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin]. ( Kleckow, M, 1991)
"The efficacy and safety of ofloxacin 400 mg once daily and amoxycillin/clavulanic acid 500/125 mg three times daily were compared in a double-blind manner in patients with an acute exacerbation of chronic bronchitis."5.06A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis. ( Beumer, HM; Hoepelman, IM; Möllers, MJ; Overbeek, BP; Rademaker, CM; Rozenberg-Arska, M; Sips, AP; Verhoef, J, 1990)
"Ofloxacin is highly active against common respiratory pathogens including Haemophilus influenzae and Branhamella catarrhalis and has clinically applicable activity against Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa."5.06Overview of experience with ofloxacin in respiratory tract infection. ( Ball, P, 1990)
"In a double-blind study in 84 patients with chronic bronchitis and purulent exacerbations, ofloxacin 200 mg b."5.06A comparative study of ofloxacin and pivmecillinam in acute exacerbations of chronic bronchitis. ( Egede, F; Kristensen, I, 1990)
"192 patients, most of them ambulatory, with acute exacerbation of chronic bronchitis were treated with 10- to 14-day courses of oral ofloxacin receiving 400 mg once daily or doxycycline first 200 mg and then 100 mg once daily in this randomized observer-blinded multicentre study."5.06Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis. ( Ammälä, K; Aro, A; Backman, R; Keistinen, T; Lehtipuu, AL; Punakivi, L; Saarelainen, P; Veneskoski, T; Vilkka, V, 1990)
"In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b."5.06[Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986)
"The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections."5.06An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987)
" holarctica in a stem cell transplant recipient with chronic graft-versus-host disease who was receiving levofloxacin prophylaxis."3.79Treatment of tularemia in patient with chronic graft-versus-host disease. ( Kaufmann, M; Knabbe, C; Seibold, E; Splettstoesser, W; Weile, J, 2013)
"The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices."3.77[Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011)
"Studies of acute exacerbations of chronic bronchitis (EXCB) included in the approval documents of levofloxacin (LVF) were reviewed in light of the good conditions of use defined by the French marketing approval and the AFSSAPS recommendations."3.72[Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors]. ( Brumpt, I; Veyssier, P; Zuck, P, 2004)
"This study was conducted to evaluate the activity of levofloxacin in comparison with a range of antibacterial agents against recent isolates obtained consecutively from patients with community-acquired pneumonia (CAP) or acute exacerbation of chronic bronchitis (AECB) during the period 1995 to 1996."3.70Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. ( Ariza, H; Ascoli, M; Casellas, JM; Dolmann, A; Gilardoni, M; Goldberg, M; Ivanovic, S; Montero, JM; Orduna, M; Tome, G, 1999)
"Sixty outpatients at the age of 65 to 75 years with exacerbated chronic bronchitis were treated with antibiotics: amoxycillin/clavulanic acid (20 patients), cefaclor (20 patients) and ciprofloxacin (20 patients)."3.69[Treatment of lower respiratory tract infections in the elderly]. ( Belousov, IuB; Efremenkova, OV; Komarova, VP; Sokolov, AV; Tishchenkova, IF, 1997)
"Two different oral ofloxacin regimens, a daily single-dose regimen with 200 mg (Regimen I) and an every-two-week multidose regimen with 3 x 200 mg/day (Regimen II) was compared as to the efficacy in controlling repeated acute exacerbations of chronic respiratory tract infections."3.69Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections. ( Motomiya, M; Nukiwa, T; Oizumi, K; Watanabe, A, 1995)
"Simultaneous bronchial biopsy and serum samples were obtained from 14 patients after a single oral dose of 200 mg ofloxacin and from ten patients during the course of multiple dose oral treatment, (200 mg ofloxacin bd) for acute exacerbations of chronic bronchitis."3.68Bronchial penetration of ofloxacin after single and multiple oral dosage. ( Davey, PG; Precious, E; Winter, J, 1991)
"Ofloxacine (Tarivid-Hoechst) was used in 30 patients with infections of the respiratory system, including 12 with pneumonias, 18 with chronic bronchitis."3.68[Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract]. ( Chyrek-Borowska, S; Jakubicz, P; Siergiejko, Z, 1991)
"In order to determine the efficacy and safety of the new quinolone ofloxacin in the treatment of chronic lower respiratory disease, 674 patients (353 with chronic bronchitis, 212 with community-acquired pneumonia and 109 with hospital-acquired pneumonia) were treated with ofloxacin 200 mg twice a day."3.68Ofloxacin in lower respiratory tract infections. ( Petermann, W, 1991)
"After ascertaining the bacterial spectrum in 105 patients with Otitis media acutissima, Otitis media chronica mesotympanalis and Otitis media chronica epitympanalis, the efficacy of oral therapy with ofloxacin in five patients from each of these groups was assessed."3.67[Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences]. ( Lenarz, T, 1986)
"The clinical efficacy and the safety of ofloxacin in lower respiratory tract infections were evaluated by 42 research groups in Japan."3.67Clinical evaluation of ofloxacin in lower respiratory tract infections. ( Kobayashi, H, 1986)
"After ascertaining the bacterial spectrum in 210 patients with Otitis media acuta, Otitis media chronica mesotympanalis and Otitis media chronica epitympanalis, the clinical efficacy of oral therapy with ofloxacin in 40 patients from each of these groups was assessed."3.67Ofloxacin in oral chemotherapy of acute and chronic otitis media. ( Lenarz, T, 1986)
" In the present study, the efficacy and safety of ofloxacin alone (OA) and the ofloxacin + dexamethasone combination (ODC) is compared by studying clinical cure rates and adverse drug reactions in patients with CSOM."2.80Efficacy and safety of ofloxacin and its combination with dexamethasone in chronic suppurative otitis media. A randomised, double blind, parallel group, comparative study. ( Jha, S; Mandavia, D; Panchasara, A; Singh, A; Tripathi, C, 2015)
"Sarcoidosis is a chronic granulomatous disease for which there are limited therapeutic options."2.78Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. ( Aboud, C; Algood, H; Boyd, AS; Braun, N; Burke, VE; Drake, WP; Isom, J; Kaminski, N; King, LE; Oswald-Richter, K; Pandit, KV; Richmond, BW; Taylor, T; Yu, C, 2013)
"Ofloxacin eardrops were effective in the initial treatment of active chronic suppurative otitis media."2.67Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. ( Chau, PY; Hui, Y; Lau, SK; Wei, WI; Wong, S; Wong, SF; Yuen, PW, 1994)
"Ofloxacin was administered orally at a daily dosage of 300 mg and 600 mg in three divided doses for 14 days to 24 and 60 patients with chronic complicated urinary infections, respectively, in order to evaluate the therapeutic efficacy."2.67[Clinical evaluation of ofloxacin in the treatment of chronic complicated urinary tract infection]. ( Hisazumi, H; Kobashi, K; Koizumi, H; Motoi, I; Nagano, K; Nishino, A; Orito, M; Sawaki, M; Shyoda, R; Uchibayashi, T, 1990)
"Two cases of chronic, cavernous pulmonary tuberculosis with bacilli resistant to several drugs are presented."2.66[2 cases of drug-resistant pulmonary tuberculosis treated with ofloxacin]. ( Krakówka, P; Krasucka-Kluźniak, A, 1989)
"Ofloxacin kinetics were influenced by renal dysfunction encountered in patients with ascites."2.38Pharmacokinetics of fluoroquinolones in hepatic failure. ( Gaillot, J; Montay, G, 1990)
" Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability."1.40Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. ( Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J, 2014)
"Levofloxacin treatment did not affect the cytokine mRNA level and nuclear factor-κB-dependent promoter activity."1.37Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. ( Dudley, MN; Griffith, DC; Lomovskaya, O; Sabet, M; Tarazi, Z; Tsivkovskii, R, 2011)
"Bronchopulmonary sequestration is a rare malformation characterized by lung tissue fed by one or several aberrant systemic arteries."1.36[Persistent pleuropneumopathy in a young woman]. ( Abada, D; Aouina, H; Baccar, MA; Ben Amar, J; Bouacha, H; Dhahri, B; El Gharbi, L; Kilani, T; Saloua, S, 2010)
"Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml."1.36In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010)
"Bacterial prostatitis is documented at a very low prevalence (7-13% of prostatitis overall considered) due to either reduced utilization of viral and bacteriological tests (Meares test, urethral swab, bacterial and viral PCR) or to the possibility that individual patients show a scarce expression of bacterial disease in biological fluids, because of intraglandular biofilm presence, with subsequent spreading of the sole plankton microrganisms."1.35[Chronic prostatitis and biofilm]. ( Bartoletti, R; Cai, T, 2009)
"Ofloxacin was susceptible on all isolates."1.32Bacteriology of chronic suppurative otitis media in congolese children. ( Muyunga, CK; Nyembue, DT; Sabue, MJ; Tshiswaka, JM, 2003)
"Encrusted cystitis is a type of severe cystitis, which progresses chronically and is characterized by excessively alkaline urine and calcifications within the bladder wall."1.32[Two cases of encrusted cystitis]. ( Arai, Y; Ichioka, K; Matsui, Y; Ohara, H; Terada, N; Terai, A; Yoshimura, K, 2004)
"We report a chronic case of pulmonary tuberculosis in a Malagasy citizen from Antsohihy (West of Madagascar), who was infected with a multi-drug resistant Mycobacterium bovis strain."1.32[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar]. ( Andrianasolo, D; Ramarokoto, H; Ramaroson, F; Rasolofo Razanamparany, V; Rasolonavalona, T; Ratsimba, L; Razafitsiarovana, I; Vincent, V, 2003)
"25 mL in children with chronic suppurative otitis media and perforated tympanic membrane, with serial sampling of otorrhea and serum up to 8 hours after dosing and middle ear mucosa up to 2 hours after dosing."1.30Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations. ( Furuta, S; Katsuda, K; Kiyota, R; Miyazaki, Y; Nobori, T; Ohyama, M; Ueno, K, 1999)
"Ofloxacin treatment gave good result in reduction of otorrhea, regardless of the earlier treatment of chronic otitis media."1.30[Clinical success of treatment of chronic otitis media using topical and peroral administration of ofloxacin]. ( Dzelalija, B; Kovacić, M, 1999)
"Levofloxacin was given to each patient at a dose of 300 mg or 400 mg a day for 7-14 days (average 12."1.28[Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis]. ( Horiba, M; Suzuki, K, 1992)

Research

Studies (156)

TimeframeStudies, this research(%)All Research%
pre-199017 (10.90)18.7374
1990's69 (44.23)18.2507
2000's51 (32.69)29.6817
2010's15 (9.62)24.3611
2020's4 (2.56)2.80

Authors

AuthorsStudies
Hameed P, S1
Patil, V1
Solapure, S1
Sharma, U1
Madhavapeddi, P1
Raichurkar, A1
Chinnapattu, M1
Manjrekar, P1
Shanbhag, G1
Puttur, J1
Shinde, V1
Menasinakai, S1
Rudrapatana, S1
Achar, V1
Awasthy, D1
Nandishaiah, R1
Humnabadkar, V1
Ghosh, A1
Narayan, C1
Ramya, VK1
Kaur, P1
Sharma, S1
Werngren, J1
Hoffner, S1
Panduga, V1
Kumar, CN1
Reddy, J1
Kumar K N, M1
Ganguly, S1
Bharath, S1
Bheemarao, U1
Mukherjee, K1
Arora, U1
Gaonkar, S1
Coulson, M1
Waterson, D1
Sambandamurthy, VK1
de Sousa, SM1
Ma, WJ1
Wu, ZR1
Yang, Q1
Hu, HJ1
Wang, JK1
Shi, YJ1
Li, FY1
Cheng, NS1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y2
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y3
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L2
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z3
Liang, C1
Yang, H2
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X2
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z2
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H2
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A2
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X2
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X2
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Chong, LY1
Head, K1
Webster, KE1
Daw, J1
Richmond, P1
Snelling, T1
Bhutta, MF1
Schilder, AG1
Burton, MJ1
Brennan-Jones, CG1
Santa Maria, PL1
Kaufman, AC1
Bacacao, B1
Thai, A1
Xia, A1
Cao, Z1
Fouad, A1
Bekale, LA1
Weile, J1
Seibold, E1
Knabbe, C1
Kaufmann, M1
Splettstoesser, W1
Drake, WP1
Oswald-Richter, K1
Richmond, BW1
Isom, J1
Burke, VE1
Algood, H1
Braun, N1
Taylor, T1
Pandit, KV1
Aboud, C1
Yu, C1
Kaminski, N1
Boyd, AS1
King, LE1
Panchasara, A1
Mandavia, D1
Jha, S1
Tripathi, C1
Bakshi, SS1
Naber, KG2
Roscher, K2
Botto, H1
Schaefer, V1
Videler, WJ1
van Drunen, CM1
Reitsma, JB1
Fokkens, WJ1
Yactayo-Miranda, Y1
Ta, CN1
He, L1
Kreutzer, TC1
Nentwich, MM1
Kampik, A1
Mino de Kaspar, H1
Bartoletti, R1
Cai, T1
Guss, J1
Abuzeid, WM1
Doghramji, L1
Edelstein, PH1
Chiu, AG1
King, P1
Lomovskaya, O2
Griffith, DC2
Burns, JL1
Dudley, MN2
Tsivkovskii, R1
Sabet, M1
Tarazi, Z1
Ben Amar, J1
Saloua, S1
Dhahri, B1
Abada, D1
Kilani, T1
Baccar, MA1
Aouina, H1
El Gharbi, L1
Bouacha, H1
Wagenlehner, F1
Boyd, NH1
Gottschall, JA1
Turvey, SE1
Leo, SH1
Boos, A1
Deans, GD1
Prendiville, J1
Crawford, RI1
Senger, C1
Conley, ME1
Tilley, P1
Junker, A1
Janz, L1
Azana, R1
Hoang, L1
Morton, TL1
Ibarz Barberá, M1
García González, M1
Teus Guezala, M1
Azoicai, D1
Antoniu, SA1
Liang, P1
Yang, W1
Zhou, P1
Huang, XK1
Liu, JW1
Chao, WF1
Wang, QT1
Balasubramanian, A1
Mohamad, I1
Sidek, D1
Zuck, P2
Vishnevskiĭ, BI1
Narvskaia, OV1
Mokrousov, IV1
Istomin, EA1
Otten, TF1
Gao, Q1
Odagiri, S2
Watanuki, Y1
Takahashi, H1
Shimada, J1
Zhou, LQ1
Shen, M1
Seo, SI1
Lee, SJ1
Kim, JC1
Choi, YJ1
SW, SW1
Hwang, TK1
Cho, YH1
Bundrick, W1
Heron, SP1
Ray, P1
Schiff, WM1
Tennenberg, AM3
Wiesinger, BA1
Wright, PA1
Wu, SC2
Zadeikis, N2
Kahn, JB3
Nickel, JC2
Downey, J2
Clark, J2
Casey, RW1
Pommerville, PJ1
Barkin, J1
Steinhoff, G1
Brock, G1
Patrick, AB1
Flax, S1
Goldfarb, B1
Palmer, BW1
Zadra, J1
Nyembue, DT1
Tshiswaka, JM1
Sabue, MJ1
Muyunga, CK1
Ohara, H1
Yoshimura, K1
Terada, N1
Ichioka, K1
Matsui, Y1
Terai, A1
Arai, Y1
Blasi, F1
Sethi, S1
Fogarty, C1
Fulambarker, A1
Ferrer, C1
Ruiz-Moreno, JM1
Rodríguez, A1
Montero, J1
Alió, JL1
Ramarokoto, H1
Andrianasolo, D1
Rasolonavalona, T1
Ramaroson, F1
Razafitsiarovana, I1
Vincent, V1
Ratsimba, L1
Rasolofo Razanamparany, V1
Veyssier, P1
Brumpt, I1
Volkov, IK1
Katosova, LK1
Davydova, IV1
Kliukina, LP1
Shcherbakova, NIu1
Liang, Q1
Luo, S1
Li, R1
Jin, X1
Martinez, FJ1
Grossman, RF2
Fisher, AC2
Walker, K1
Ambruzs, ME1
Schaeffer, AJ1
Smelov, V1
Perekalina, T1
Artemenko, N1
Smelova, N1
Ukleeva, G1
Gorelov, A1
Healy, B1
Llewelyn, M1
Westmoreland, D1
Lloyd, G1
Brown, N1
Giamarellou, H1
Kanellakopoulou, K1
Esposito, S1
Noviello, S1
Leone, S1
Ianniello, F1
Ascione, T1
Gaeta, GB1
Olapade-Olaopa, EO1
Adebayo, SA1
Ambrusz, ME1
Khashab, MM1
Pea, F1
Marioni, G1
Pavan, F1
Staffieri, C1
Bottin, R1
Staffieri, A1
Furlanut, M1
Xu, H1
Shang, XJ1
Teng, WH1
Huang, YF1
Yamamoto, A1
Konishi, I1
Kumata, M1
Giannarini, G1
Mogorovich, A1
Valent, F1
Morelli, G1
De Maria, M1
Manassero, F1
Barbone, F1
Selli, C1
Tazi, A1
Gueudet, T1
Varon, E1
Gilly, L1
Trieu-Cuot, P1
Poyart, C1
Guo, DF1
Zhang, HZ1
Wang, HP1
Watanabe, A2
Oizumi, K1
Motomiya, M1
Nukiwa, T1
Elliott, AM1
Berning, SE1
Iseman, MD1
Peloquin, CA1
Sumitsawan, Y1
Tharavichitkul, P1
Prawatmuang, W1
Ingsuwan, B1
Sriburi, P1
Supiyaphun, P2
Tonsakulrungruang, K1
Chochaipanichnon, L1
Chongtateong, A1
Samart, Y1
Yuen, AP1
Chau, PY2
Wei, WI2
Savitskaia, KI1
Tsar'kova, LN1
Shanina, AG1
Nasonov, VN1
Solodilova, OE1
Rusanova, EV1
Koizumi, F1
Ohnishi, A1
Takemura, H1
Okubo, S1
Kagami, T1
Tanaka, T1
Ohkawa, M1
Yamaguchi, K1
Tokunaga, S1
Nakashima, T1
Shoda, R1
Koch, K1
Drewelow, B1
Brinckmann, W1
Henry-Suchet, J1
Tannous, W1
Gehanno, P1
Cohen, B1
Heppt, W1
Lutz, H1
Husfeldt, P1
Egede, F2
Nielsen, PB1
Gaillot, O1
Berche, P1
Kawahara, S1
Watanabe, Y1
Matsuka, Y1
Sato, T1
Takahashi, K1
Sufarlan, AW1
Zainudin, BM1
Pit, S1
Ishak, I1
Watanabe, K1
Yoshida, M1
Ishibashi, T1
Kido, M1
Hirose, T1
Maeda, F1
Matsuzaki, Y1
Yuen, PW1
Lau, SK1
Hui, Y1
Wong, SF1
Wong, S1
Riley, UB1
Bignardi, G1
Goldberg, L1
Johnson, AP1
Holmes, B1
Tong, MC2
Woo, JK1
van Hasselt, CA2
Tsutsumi, M1
Takada, A1
Takase, S1
Sawada, M1
Vittver, V1
Ketterl', R1
Nonikov, VE1
Lenkova, NI1
Makarova, OV1
Ritchik, LA1
Pytel', IuA1
Volkova, VS1
Bruguera, M1
Kaga, K1
Ichimura, K1
Komarova, VP1
Belousov, IuB2
Sokolov, AV2
Tishchenkova, IF1
Efremenkova, OV2
Michałowska-Mitczuk, D1
Kuś, J1
DeAbate, CA1
Henry, D1
Bensch, G1
Jubran, A1
Chodosh, S2
Harper, L1
Tipping, D1
Talbot, GH1
Kaplanski, G1
Granel, B1
Vaz, T1
Durand, JM1
Ohyama, M1
Furuta, S1
Ueno, K1
Katsuda, K1
Nobori, T1
Kiyota, R1
Miyazaki, Y2
Enin, IP1
Shah, PM3
Maesen, FP5
Dolmann, A2
Vetter, N1
Fiss, E1
Wesch, R1
Casellas, JM1
Gilardoni, M1
Tome, G1
Goldberg, M1
Ivanovic, S1
Orduna, M1
Ascoli, M1
Ariza, H1
Montero, JM1
Davies, BI4
Kovacić, M1
Dzelalija, B1
El'kun, GB1
Greenberg, RN1
Newman, MT1
Shariaty, S1
Pectol, RW1
Fujita, A1
Miya, T1
Tanaka, R1
Hirayama, S1
Isaka, H1
Ono, Y1
Koshiishi, Y1
Goya, T1
Tishenkova, IF1
Kerekhanjanarong, V1
Koranasophonepun, J1
Sastarasadhit, V1
Potts, JM1
Ward, AM1
Rackley, RR1
Guseĭnov, KhIu1
Gomis, M1
Barberán, J1
Sánchez, B1
Khorrami, S1
Borja, J1
García-Barbal, J1
Yanagihara, K1
Tomono, K1
Sawai, T1
Kuroki, M1
Kaneko, Y1
Ohno, H1
Higashiyama, Y1
Hirakata, Y1
Maesaki, S1
Kadota, J1
Tashiro, T1
Kohno, S1
Klein, JO2
Bluestone, CD1
McCracken, GH1
Li-McLeod, J1
Perfetto, EM1
Johnston, B1
Budanov, SV1
Vasil'ev, AN1
Smirnova, LB1
Senneville, E1
Yazdanpanah, Y1
Cazaubiel, M1
Cordonnier, M1
Valette, M1
Beltrand, E1
Khazarjian, A1
Maulin, L1
Alfandari, S1
Caillaux, M1
Dubreuil, L1
Mouton, Y1
Yue, V1
Ku, PK1
van Hasselt, P1
van Kregten, E1
Jung, HH1
Cho, SD1
Yoo, CK1
Lim, HH1
Chae, SW1
Marcos Sánchez, F1
Aparicio Martínez, JC1
Celdrán Gil, J1
Durán Pérez-Navarro, A1
Nakamori, Y1
Tsuboi, E1
Narui, K1
Nakatani, T1
Nakata, K1
Sugi, H1
Romano, L1
Girosi, D1
Spallone, E1
Parisi, F1
Minicucci, L1
Romano, C1
Yew, WW1
Lee, J1
Suzuki, K1
Horiba, M1
Maier, H1
Attallah, M1
Jünemann, KH1
Petermann, W1
Boye, NP1
Gaustad, P1
Kimura, S1
Toda, H1
Shimabukuro, Y1
Kitamura, M1
Fujimoto, N1
Miki, Y1
Okada, H2
Chyrek-Borowska, S1
Siergiejko, Z1
Jakubicz, P1
Kleckow, M1
Davey, PG1
Precious, E1
Winter, J1
Gentry, LO1
Rodriguez-Gomez, G1
Yamaoka, M1
Fukuchi, Y1
Yokouchi, M1
Teramoto, N1
Nagase, T1
Ishida, K1
Ohtomo, E1
Orimo, H1
De Simone, C1
Di Fabio, S1
Moretti, S1
Tzantzoglou, S1
Trinchieri, V1
Gargiulo, M1
Punakivi, L1
Keistinen, T1
Backman, R1
Lehtipuu, AL1
Saarelainen, P1
Vilkka, V1
Veneskoski, T1
Ammälä, K1
Aro, A1
Kristensen, I1
Ball, P1
Uchibayashi, T1
Nishino, A1
Motoi, I1
Hisazumi, H1
Sawaki, M1
Orito, M1
Koizumi, H1
Shyoda, R1
Nagano, K1
Kobashi, K1
Montay, G1
Gaillot, J1
Kiriushchenkov, AP1
Rademaker, CM1
Sips, AP1
Beumer, HM1
Hoepelman, IM1
Overbeek, BP1
Möllers, MJ1
Rozenberg-Arska, M1
Verhoef, J1
Krasucka-Kluźniak, A1
Krakówka, P1
Takamori, A1
Yamagami, H1
Ozaki, M1
Yamanaka, H1
Umemoto, S1
Sakamoto, T1
Suginaka, H1
Davis, GJ1
McKenzie, BE1
Löffler, A1
Grafvon Westphalen, H1
Teengs, JP1
Baur, C3
Geraedts, WH1
Jensen, T1
Pedersen, SS1
Høiby, N1
Koch, C1
Hasçelik, G1
Lenarz, T2
Sumajow, CA1
Kobayashi, H1
Sugimoto, Y1
Matsumoto, Y1
Hitsuda, Y1
Yamamoto, Y1
Ishitobi, K1
Sasaki, T1
Ketterl, R1
Beckurts, T1
Stübinger, B1
Claudi, B1
Harazim, H1
Wimmer, J1
Mittermayer, HP1
Knothe, H1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis[NCT01074554]Phase 1/Phase 230 participants (Actual)Interventional2010-02-28Completed
A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis[NCT00236808]Phase 3383 participants (Actual)Interventional2000-05-31Completed
A Study to Understand the Treatment Patterns in Patients With Chronic Bacterial Prostatitis (Category II), Chronic Pelvic Pain (Category IIIA, IIIB)Treataprost Added to Standard Antibiotic Treatment in Real-life Clinical Practice[NCT05306314]140 participants (Anticipated)Observational2022-04-15Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions

(NCT01074554)
Timeframe: Baseline to 8 weeks

Interventionmm (Median)
Antibiotic Regimen-8.4
Placebo Regimen0.07

Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.

Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe). (NCT01074554)
Timeframe: Baseline to 8 weeks

Interventionunits on a scale (Mean)
Antibiotic Regimen-2.9
Placebo Regimen-0.6

Granuloma Burden

Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy) (NCT01074554)
Timeframe: Baseline to 8 weeks

Interventionparticipants (Number)
Antibiotic Regimen7
Placebo Regimen0

Reviews

14 reviews available for ofloxacin and Chronic Illness

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Topical versus systemic antibiotics for chronic suppurative otitis media.
    The Cochrane database of systematic reviews, 2021, 02-09, Volume: 2

    Topics: Administration, Topical; Adult; Aminoglycosides; Amoxicillin-Potassium Clavulanate Combination; Anti

2021
Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia.
    Journal of clinical immunology, 2012, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Agammaglobulinemia; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Chronic Di

2012
MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:2

    Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Clinical Trials as Topic; Drug D

2013
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 2

    Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infecti

2004
[Treatment of chronic hepatitis C: still many problems pending].
    Gastroenterologia y hepatologia, 1997, Volume: 20, Issue:1

    Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiv

1997
The use of levofloxacin in the treatment of respiratory tract infection.
    Journal of chemotherapy (Florence, Italy), 2000, Volume: 12 Suppl 4

    Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infec

2000
In vitro and in vivo antimicrobial activity of topical ofloxacin and other ototopical agents.
    The Pediatric infectious disease journal, 2001, Volume: 20, Issue:1

    Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Local; Chronic Disease; Clinical Trials

2001
Efficacy of ofloxacin and other ototopical preparations for chronic suppurative otitis media in children.
    The Pediatric infectious disease journal, 2001, Volume: 20, Issue:1

    Topics: Anti-Infective Agents; Anti-Infective Agents, Local; Bacteria; Child; Chronic Disease; Humans; Middl

2001
The use of topical ofloxacin for otic diseases in infants and children. Summary and conclusions.
    The Pediatric infectious disease journal, 2001, Volume: 20, Issue:1

    Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Local; Chronic Disease; Humans; Middle

2001
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2001, Volume: 46, Issue:7

    Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infec

2001
Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.
    The American journal of medicine, 1991, Dec-30, Volume: 91, Issue:6A

    Topics: Acute Disease; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Fluoroquinolones;

1991
Pharmacokinetics of fluoroquinolones in hepatic failure.
    The Journal of antimicrobial chemotherapy, 1990, Volume: 26 Suppl B

    Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Ha

1990
Toxicologic evaluation of ofloxacin.
    The American journal of medicine, 1989, Dec-29, Volume: 87, Issue:6C

    Topics: Abnormalities, Drug-Induced; Acute Disease; Animals; Chronic Disease; Dogs; Ofloxacin; Rats

1989

Trials

64 trials available for ofloxacin and Chronic Illness

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.
    JAMA dermatology, 2013, Volume: 149, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; CD4-Positive T-Lymphocytes;

2013
Efficacy and safety of ofloxacin and its combination with dexamethasone in chronic suppurative otitis media. A randomised, double blind, parallel group, comparative study.
    Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2015, Volume: 35, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Dexamethasone; Double-Blind Method; Drug Therapy, Com

2015
Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis.
    International journal of antimicrobial agents, 2008, Volume: 32, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Chronic Disease; Gram-Negative Bacteria; Gram-Po

2008
Nebulized bacitracin/colimycin: a treatment option in recalcitrant chronic rhinosinusitis with Staphylococcus aureus? A double-blind, randomized, placebo-controlled, cross-over pilot study.
    Rhinology, 2008, Volume: 46, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacitracin; Chron

2008
A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2009, Volume: 247, Issue:7

    Topics: Administration, Topical; Anti-Bacterial Agents; Blepharitis; Chronic Disease; Colony Count, Microbia

2009
Assessing the efficacy of tragal pumping: a randomized controlled trial.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2011, Volume: 144, Issue:6

    Topics: Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Ear Canal; Fem

2011
[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].
    Zhonghua nan ke xue = National journal of andrology, 2012, Volume: 18, Issue:10

    Topics: Adult; Capsules; Chronic Disease; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Levofloxacin;

2012
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
    Urology, 2003, Volume: 62, Issue:3

    Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Met

2003
Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial.
    Urology, 2003, Volume: 62, Issue:4

    Topics: Adult; Aged; Anti-Infective Agents; Chronic Disease; Double-Blind Method; Humans; Levofloxacin; Male

2003
A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Respiratory medicine, 2004, Volume: 98, Issue:8

    Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Double-Blind

2004
[Efficacy of levofloxacin (Tavanic) in the treatment of children with chronic pulmonary diseases].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2004, Volume: 49, Issue:7

    Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Bronchopneumonia; Child; Chronic Disease; H

2004
Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.
    The European respiratory journal, 2005, Volume: 25, Issue:6

    Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Amoxicillin-Potassium Clavul

2005
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
    The Journal of urology, 2005, Volume: 174, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections;

2005
Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients.
    Clinical therapeutics, 2006, Volume: 28, Issue:8

    Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; Br

2006
[Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis].
    Zhonghua nan ke xue = National journal of andrology, 2007, Volume: 13, Issue:4

    Topics: Adult; Chronic Disease; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Phytotherapy; Prostatiti

2007
Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Dioxolanes; Double-Blind Method; Fluoroquinolones; Hu

2007
[Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis].
    Zhonghua nan ke xue = National journal of andrology, 2008, Volume: 14, Issue:1

    Topics: Adult; Anti-Infective Agents, Urinary; Capsules; Chronic Disease; Drug Therapy, Combination; Drugs,

2008
The treatment of chronic suppurative otitis media and otitis externa with 0.3 per cent ofloxacin otic solution: a clinico-microbiological study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1995, Volume: 78, Issue:1

    Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Chronic Disease; Hum

1995
[Use of ofloxacin in the treatment of infections of the lower respiratory tract].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1994, Volume: 39, Issue:6

    Topics: Adolescent; Adult; Asthma; Bronchitis; Chronic Disease; Female; Gram-Negative Bacterial Infections;

1994
Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum.
    Urologia internationalis, 1993, Volume: 51, Issue:3

    Topics: Adult; Aged; Chronic Disease; Humans; Leukocyte Count; Male; Middle Aged; Minocycline; Ofloxacin; Pr

1993
[Medical management of chronic Chlamydia trachomatis salpingitis resistant to usual antibiotics. Use of ofloxacin alone or combined with other anti-chlamydia antibiotics].
    Contraception, fertilite, sexualite (1992), 1993, Volume: 21, Issue:9

    Topics: Adult; Chlamydia Infections; Chlamydia trachomatis; Chronic Disease; Doxycycline; Drug Resistance, M

1993
Effectiveness and safety of ofloxacin in chronic otitis media and chronic sinusitis in adult outpatients.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1993, Volume: 250 Suppl 1

    Topics: Administration, Oral; Adult; Ambulatory Care; Bacterial Infections; Chronic Disease; Humans; Ofloxac

1993
Clinical experiences with ofloxacin sequential therapy in chronic ear infections.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1993, Volume: 250 Suppl 1

    Topics: Administration, Oral; Adult; Bacterial Infections; Chronic Disease; Drug Administration Schedule; Fe

1993
Antibiotic treatment of sinusitis in general practice. A double-blind study comparing ofloxacin and erythromycin.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1993, Volume: 250 Suppl 1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Erythromycin; Fami

1993
Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
    Drugs, 1995, Volume: 49 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Cross

1995
Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.
    Drugs, 1995, Volume: 49 Suppl 2

    Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chronic Disease; Female; Humans; Male; Middle Aged;

1995
Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
    Drugs, 1995, Volume: 49 Suppl 2

    Topics: Anti-Infective Agents; Chronic Disease; Humans; Ofloxacin; Respiratory Tract Infections

1995
Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study.
    The American journal of otology, 1994, Volume: 15, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combin

1994
A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media.
    The Journal of laryngology and otology, 1996, Volume: 110, Issue:4

    Topics: Anti-Infective Agents; Chronic Disease; Double-Blind Method; Drug Combinations; Humans; Hydrocortiso

1996
[Chronic osteitis--modern therapy].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1996, Volume: 41, Issue:9

    Topics: Administration, Oral; Anti-Infective Agents; Chronic Disease; Drug Administration Schedule; Enteroba

1996
[Stepdown ofloxacin therapy in bronchopulmonary diseases].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1996, Volume: 41, Issue:9

    Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Drug Administration Schedu

1996
[Comprehensive treatment with ofloxacin in pyo-inflammatory urologic diseases].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1996, Volume: 41, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Infective Agents, Urinary; Anti-Inflammatory

1996
A preliminary report: clinical effects of otic solution of ofloxacin in infantile myringitis and chronic otitis media.
    International journal of pediatric otorhinolaryngology, 1998, Volume: 42, Issue:3

    Topics: Anti-Infective Agents; Child; Chronic Disease; Female; Humans; Male; Ofloxacin; Otitis Media with Ef

1998
Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
    Chest, 1998, Volume: 114, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chlamy

1998
Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
    The Journal of antimicrobial chemotherapy, 1999, Volume: 43, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chron

1999
Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.
    The Journal of antimicrobial chemotherapy, 1999, Volume: 43 Suppl C

    Topics: Aged; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chronic Disease; Double-Blind M

1999
[Effectiveness of maxaquin and tarivid in combined therapy of patients with chronic sinusitis].
    Vestnik otorinolaringologii, 1999, Issue:6

    Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antitubercular Agents; Chronic Disease; Drug Therapy

1999
Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:1

    Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Fluoroquinolones; Follow-Up St

2000
[The importance of fluoroquinolones in treating pneumonia in the elderly].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1999, Volume: 44, Issue:12

    Topics: Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Fluoroqu

1999
Comparison of ofloxacin otic solution with oral amoxycillin plus chloramphenicol ear drop in treatment of chronic suppurative otitis media with acute exacerbation.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2000, Volume: 83, Issue:1

    Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective

2000
Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 1999, Volume: 12, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Chronic Disease; Cilast

1999
Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial.
    The Journal of urology, 2001, Volume: 165, Issue:5

    Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibodies, Bacterial; Bacteria; Bacterial In

2001
Preoperative topical ofloxacin solution for tympanoplasty: a randomized, controlled study.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2002, Volume: 23, Issue:1

    Topics: Adult; Anti-Infective Agents; Chronic Disease; Female; Humans; Male; Myringoplasty; Ofloxacin; Otiti

2002
A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1992, Volume: 73, Issue:1

    Topics: Adult; Aged; Antitubercular Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Resistan

1992
[The use of ofloxacin in cystic fibrosis patients].
    Minerva pediatrica, 1992, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Analysis of Variance; Chronic Disease; Cystic Fibrosis; Drug Tolerance; Female; H

1992
Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.
    Infection, 1991, Volume: 19 Suppl 7

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchiectasis; Bronchitis; Chr

1991
Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease.
    Infection, 1991, Volume: 19 Suppl 7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchitis; Chronic Disease; Double-Blind Method; Female

1991
Topical chemotherapy in human periodontitis using a new controlled-release insert containing ofloxacin. I. Microbiological observation.
    Journal of periodontal research, 1991, Volume: 26, Issue:1

    Topics: Administration, Topical; Adult; Analysis of Variance; Bacteria; Chronic Disease; Colony Count, Micro

1991
[Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin].
    Fortschritte der Medizin, 1991, Jul-30, Volume: 109, Issue:22

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Cefuroxime; Chronic Di

1991
Ofloxacin versus parenteral therapy for chronic osteomyelitis.
    Antimicrobial agents and chemotherapy, 1991, Volume: 35, Issue:3

    Topics: Administration, Oral; Adult; Aged; Cefazolin; Ceftazidime; Chronic Disease; Female; Gram-Negative Ba

1991
Open randomized controlled parallel study of ofloxacin versus trimethoprim-sulfamethoxazole treatment of lower respiratory tract and urinary infections.
    Chemotherapy, 1991, Volume: 37 Suppl 1

    Topics: Acute Disease; Aged; Bronchitis; Bronchopneumonia; Chronic Disease; Cystitis; Escherichia coli; Fema

1991
Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis.
    Scandinavian journal of infectious diseases. Supplementum, 1990, Volume: 68

    Topics: Administration, Oral; Bronchitis; Chronic Disease; Doxycycline; Drug Administration Schedule; Female

1990
A comparative study of ofloxacin and pivmecillinam in acute exacerbations of chronic bronchitis.
    Scandinavian journal of infectious diseases. Supplementum, 1990, Volume: 68

    Topics: Adult; Aged; Aged, 80 and over; Amdinocillin Pivoxil; Bronchitis; Chronic Disease; Double-Blind Meth

1990
Overview of experience with ofloxacin in respiratory tract infection.
    Scandinavian journal of infectious diseases. Supplementum, 1990, Volume: 68

    Topics: Bronchitis; Chronic Disease; Humans; Ofloxacin; Pneumonia; Remission Induction; Respiratory Tract In

1990
[Clinical evaluation of ofloxacin in the treatment of chronic complicated urinary tract infection].
    Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Humans; M

1990
A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis.
    The Journal of antimicrobial chemotherapy, 1990, Volume: 26 Suppl D

    Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Chronic Disease; Clavulanic

1990
[2 cases of drug-resistant pulmonary tuberculosis treated with ofloxacin].
    Pneumonologia polska, 1989, Volume: 57, Issue:4

    Topics: Adult; Antitubercular Agents; Chronic Disease; Clinical Trials as Topic; Drug Resistance, Microbial;

1989
[Topical chemotherapy of chronic periodontitis using controlled-release insert containing ofloxacin (PT-01) without root planing].
    Nihon Shishubyo Gakkai kaishi, 1989, Volume: 31, Issue:1

    Topics: Chronic Disease; Delayed-Action Preparations; Humans; Ofloxacin; Periodontitis

1989
The use of quinolones in respiratory tract infections.
    Drugs, 1987, Volume: 34 Suppl 1

    Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans; Microbial Sens

1987
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
    European journal of clinical microbiology, 1987, Volume: 6, Issue:6

    Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibro

1987
Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease.
    The Journal of antimicrobial chemotherapy, 1986, Volume: 18, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Chronic Disease; Drug Therapy, Combination; Fe

1986
An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections.
    Drugs, 1987, Volume: 34 Suppl 1

    Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Doxycycline; Humans; Microbial Sensitivity Tests

1987
[Respiratory tract infections--clinical results with ofloxacin].
    Infection, 1986, Volume: 14 Suppl 1

    Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Clinical Trials as

1986

Other Studies

79 other studies available for ofloxacin and Chronic Illness

ArticleYear
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
    Journal of medicinal chemistry, 2014, Jun-12, Volume: 57, Issue:11

    Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological

2014
Biliary antibiotics irrigation for E. coli-induced chronic proliferative cholangitis and hepatolithiasis: A pathophysiological study in rabbits.
    Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:3

    Topics: Animals; Anti-Bacterial Agents; Bacitracin; Chlorhexidine; Cholangitis; Chronic Disease; Collagen Ty

2020
Topical Therapy Failure in Chronic Suppurative Otitis Media is Due to Persister Cells in Biofilms.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2021, 10-01, Volume: 42, Issue:9

    Topics: Anti-Bacterial Agents; Anti-Infective Agents, Local; Biofilms; Chronic Disease; Humans; Ofloxacin; O

2021
Treatment of tularemia in patient with chronic graft-versus-host disease.
    Emerging infectious diseases, 2013, Volume: 19, Issue:5

    Topics: Anti-Bacterial Agents; Chronic Disease; Doxycycline; Francisella tularensis; Graft vs Host Disease;

2013
Comment on: Effect of topical ofloxacin on bacterial biofilms in refractory post-sinus surgery rhino-sinusitis.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016, Volume: 273, Issue:9

    Topics: Biofilms; Chronic Disease; Humans; Nose; Ofloxacin; Paranasal Sinuses; Rhinitis; Sinusitis

2016
[Chronic prostatitis and biofilm].
    Le infezioni in medicina, 2009, Volume: 17 Suppl 1

    Topics: Adult; Biofilms; Chronic Disease; Ciprofloxacin; Contraception Behavior; Diet; Disease Susceptibilit

2009
Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
    ORL; journal for oto-rhino-laryngology and its related specialties, 2009, Volume: 71, Issue:5

    Topics: Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Comorbidity; Drug Resistance, Bacterial; Fluo

2009
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1

    Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, M

2010
Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections.
    FEMS immunology and medical microbiology, 2011, Volume: 61, Issue:2

    Topics: Administration, Inhalation; Aerosols; Anti-Inflammatory Agents; Cell Line; Chronic Disease; Epitheli

2011
[Persistent pleuropneumopathy in a young woman].
    Revue de pneumologie clinique, 2010, Volume: 66, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Bronchopulmonary Sequestration; Bronchoscopy; Chronic Disease; Drug Th

2010
[Practice management of chronic bacterial prostatitis with levofloxacin].
    Aktuelle Urologie, 2011, Volume: 42, Issue:3

    Topics: Adult; Aged; Anti-Infective Agents, Urinary; Bacterial Infections; Chronic Disease; Escherichia coli

2011
[Transepithelial phototherapeutic keratectomy to treat chronic laser in situ keratomileusis-flap macrostriae. A case review].
    Archivos de la Sociedad Espanola de Oftalmologia, 2012, Volume: 87, Issue:12

    Topics: Antibiotic Prophylaxis; Astigmatism; Chronic Disease; Contact Lenses; Corneal Edema; Dexamethasone;

2012
Extensive dural sinus thrombosis and bilateral lateral rectus palsy as an uncommon complication of chronic suppurative otitis media.
    BMJ case reports, 2013, Jan-25, Volume: 2013

    Topics: Abducens Nerve Diseases; Adolescent; Anti-Bacterial Agents; Ceftriaxone; Chronic Disease; Fibrinolyt

2013
[Update on the use of levofloxacin in the management of acute exacerbations of chronic bronchitis with risk factors].
    Presse medicale (Paris, France : 1983), 2002, Jun-15, Volume: 31, Issue:21 Pt 2

    Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chron

2002
[Sensitivity to levofloxacin of Mycobacterium tuberculosis strains with various phenotype isolated from patients with newly diagnosed and chronic tuberculosis].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2002, Volume: 47, Issue:6

    Topics: Anti-Infective Agents; Chronic Disease; Drug Resistance, Bacterial; Genotype; Humans; Levofloxacin;

2002
[Clinical and bacteriology observation on intraoperation usage of tarivid otic solution in treatment of chronic otitis media with cholesteatoma].
    Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology, 1999, Volume: 13, Issue:5

    Topics: Adult; Aged; Anti-Infective Agents; Cholesteatoma, Middle Ear; Chronic Disease; Combined Modality Th

1999
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year].
    The Japanese journal of antibiotics, 2001, Volume: 54 Suppl B

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceph

2001
[Detection of bacterial 16S rRAN gene in EPS of men with chronic pelvic pain syndrome and its clinical significance].
    Zhonghua nan ke xue = National journal of andrology, 2003, Volume: 9, Issue:4

    Topics: Anti-Bacterial Agents; Azithromycin; Chronic Disease; Humans; Levofloxacin; Male; Ofloxacin; Pelvic

2003
Effects of androgen deprivation on chronic bacterial prostatitis in a rat model.
    International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:9

    Topics: Androgen Antagonists; Animals; Anti-Infective Agents, Urinary; Castration; Chronic Disease; Enzyme I

2003
Bacteriology of chronic suppurative otitis media in congolese children.
    Acta oto-rhino-laryngologica Belgica, 2003, Volume: 57, Issue:3

    Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease; Citrobacter; Congo; Fem

2003
[Two cases of encrusted cystitis].
    Hinyokika kiyo. Acta urologica Japonica, 2004, Volume: 50, Issue:1

    Topics: Aged; Aged, 80 and over; Alkalosis; Anti-Infective Agents, Urinary; Calcium Carbonate; Carbonates; C

2004
Postoperative Corynebacterium macginleyi endophthalmitis.
    Journal of cataract and refractive surgery, 2004, Volume: 30, Issue:11

    Topics: Aged; Aqueous Humor; Bacterial Typing Techniques; Cataract Extraction; Chronic Disease; Corynebacter

2004
[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar].
    Archives de l'Institut Pasteur de Madagascar, 2003, Volume: 69, Issue:1-2

    Topics: Amikacin; Antitubercular Agents; Capreomycin; Chronic Disease; Ciprofloxacin; Cough; DNA, Bacterial;

2003
[Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors].
    Revue de pneumologie clinique, 2004, Volume: 60, Issue:5 Pt 1

    Topics: Acute Disease; Anti-Bacterial Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans;

2004
Microbiological analysis of chronic dacryocystitis.
    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2005, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Ch

2005
Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome.
    Andrologia, 2005, Volume: 37, Issue:2-3

    Topics: Anti-Bacterial Agents; Chlamydia trachomatis; Chronic Disease; Fluoroquinolones; Humans; Levofloxaci

2005
The value of follow-up after acute Q fever infection.
    The Journal of infection, 2006, Volume: 52, Issue:4

    Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Chronic Disease; Complement Fixation Tests; Coxiella b

2006
A review of the therapeutic uses of ofloxacin.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bronchitis; Chronic

1989
Clinical efficacy and tolerability of levofloxacin in patients with liver disease: a prospective, non comparative, observational study.
    Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:1

    Topics: Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Drug Tolerance; Female; Humans; Levofl

2006
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
    The Journal of urology, 2006, Volume: 175, Issue:6

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin;

2006
Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose.
    Pharmacological research, 2007, Volume: 55, Issue:1

    Topics: Adult; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Chronic Disease; Female; H

2007
[Drug-resistant bacteria isolated from pharyngeal swab cultures and urine in acutely or chronically febrile elderly nursing home inmates].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2007, Volume: 44, Issue:3

    Topics: Acute Disease; Aged; Chronic Disease; Drug Resistance, Bacterial; Escherichia coli; Fever; Fluoroqui

2007
Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis.
    Emerging infectious diseases, 2008, Volume: 14, Issue:2

    Topics: Acute Disease; Aged, 80 and over; Anti-Bacterial Agents; Bronchitis; Chronic Disease; DNA Gyrase; Dr

2008
Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections.
    The Tohoku journal of experimental medicine, 1995, Volume: 176, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule;

1995
Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1995, Volume: 76, Issue:5

    Topics: Aged; Antitubercular Agents; Chronic Disease; Empyema, Tuberculous; Ethambutol; Humans; Male; Ofloxa

1995
Ofloxacin otic solution as treatment of chronic suppurative otitis media and diffuse bacterial otitis externa.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1995, Volume: 78, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Chronic Disease; Humans; In

1995
Bacteriology of chronic suppurative otitis media: ofloxacin susceptibility.
    The Journal of otolaryngology, 1995, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Female; Human

1995
Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Humans; Kidney Diseases; Male; Middle Aged;

1994
[Pancreas penetration by ofloxacin--a pilot study].
    Zeitschrift fur Gastroenterologie, 1993, Volume: 31, Issue:10

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Bile; Cholestasis, Extrahepatic; Chronic Disease; Duodenal Ne

1993
In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
    Drugs, 1995, Volume: 49 Suppl 2

    Topics: Adult; Anti-Infective Agents; Bacteria; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial;

1995
Levofloxacin in patients with severe respiratory tract infection.
    Drugs, 1995, Volume: 49 Suppl 2

    Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Asthma; Bronchitis; Chronic Disease; Clarithromy

1995
Quinolone resistance in Oligella urethralis-associated chronic ambulatory peritoneal dialysis peritonitis.
    The Journal of infection, 1996, Volume: 32, Issue:2

    Topics: Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Huma

1996
Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study.
    Journal of gastroenterology and hepatology, 1996, Volume: 11, Issue:11

    Topics: Adult; Anti-Infective Agents; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female;

1996
Sparfloxacin and levofloxacin.
    The Medical letter on drugs and therapeutics, 1997, Apr-25, Volume: 39, Issue:999

    Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic;

1997
[Treatment of lower respiratory tract infections in the elderly].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1997, Volume: 42, Issue:12

    Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; A

1997
[Treatment of patients for chronic pulmonary tuberculosis with expectoration--selection and tolerance to drugs].
    Pneumonologia i alergologia polska, 1997, Volume: 65, Issue:3-4

    Topics: Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Humans; Incidence

1997
Jarisch-Herxheimer reaction complicating the treatment of chronic Q fever endocarditis: elevated TNFalpha and IL-6 serum levels.
    The Journal of infection, 1998, Volume: 37, Issue:1

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Coxiella burnetii; Doxycycline; Drug

1998
Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations.
    Archives of otolaryngology--head & neck surgery, 1999, Volume: 125, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Child, Preschool; Chronic

1999
[Rehabilitation of patients with chronic purulent otitis media].
    Vestnik otorinolaringologii, 1999, Issue:2

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Humans; Ofloxacin; Otitis Media, Supp

1999
Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
    The Journal of antimicrobial chemotherapy, 1999, Volume: 43 Suppl C

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Commun

1999
[Clinical success of treatment of chronic otitis media using topical and peroral administration of ofloxacin].
    Lijecnicki vjesnik, 1999, Volume: 121, Issue:6

    Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-Infective Agents; Chronic Dis

1999
National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
    Sexually transmitted infections, 1999, Volume: 75 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, U

1999
[Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
    The Japanese journal of antibiotics, 1999, Volume: 52, Issue:11

    Topics: Adult; Aged; Chronic Disease; Female; Humans; Levofloxacin; Lung; Male; Middle Aged; Ofloxacin; Pneu

1999
Association of chronic urinary symptoms in women and Ureaplasma urealyticum.
    Urology, 2000, Volume: 55, Issue:4

    Topics: Adolescent; Adult; Aged; Azithromycin; Bacteriological Techniques; Bacteriuria; Chronic Disease; Cys

2000
[Use of antibiotics in chronic bronchitis].
    Problemy tuberkuleza, 2000, Issue:1

    Topics: Administration, Oral; Adult; Ampicillin; Anti-Infective Agents; Bronchitis; Chronic Disease; Female;

2000
Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:1

    Topics: Animals; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Drug Therapy, Combinatio

2000
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
    Managed care interface, 2001, Volume: 14, Issue:2

    Topics: Absenteeism; Adolescent; Adult; Anti-Infective Agents; Bronchitis; Chronic Disease; Cost of Illness;

2001
Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis.
    The Journal of antimicrobial chemotherapy, 2001, Volume: 48, Issue:6

    Topics: Administration, Oral; Aged; Anti-Infective Agents; Antibiotics, Antitubercular; Bacterial Infections

2001
Treatment of chronic suppurative otitis media with ofloxacin in hydroxypropyl methylcellulose ear drops: a clinical/bacteriological study in a rural area of Malawi.
    International journal of pediatric otorhinolaryngology, 2002, Mar-15, Volume: 63, Issue:1

    Topics: Adolescent; Adult; Anti-Infective Agents; Bacteriological Techniques; Child; Child, Preschool; Chron

2002
[Chronic bronchitis. What antibiotic in acute exacerbations. Good and fast effectiveness is needed].
    MMW Fortschritte der Medizin, 2002, Feb-14, Volume: 144, Issue:7

    Topics: Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Female; Humans; Male; Middle Aged; Ofloxac

2002
Vinegar treatment in the management of granular myringitis.
    The Journal of laryngology and otology, 2002, Volume: 116, Issue:3

    Topics: Acetic Acid; Adolescent; Adult; Anti-Infective Agents; Chronic Disease; Female; Follow-Up Studies; G

2002
[Ofloxacin in the treatment of lower respiratory tract infections in patients with chronic pulmonary diseases].
    Anales de medicina interna (Madrid, Spain : 1984), 1992, Volume: 9, Issue:8

    Topics: Chronic Disease; Humans; Lung Diseases; Ofloxacin; Respiratory Tract Infections

1992
[Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
    The Japanese journal of antibiotics, 1992, Volume: 45, Issue:5

    Topics: Aged; Chronic Disease; Drug Evaluation; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin;

1992
Drug treatment of chronic tuberculous empyema.
    Chest, 1992, Volume: 101, Issue:6

    Topics: Chronic Disease; Empyema, Tuberculous; Humans; Ofloxacin

1992
[Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis].
    Hinyokika kiyo. Acta urologica Japonica, 1992, Volume: 38, Issue:6

    Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Epididymitis; Escherichia coli; Humans;

1992
[Facial paralysis in chronic nonspecific inflammation of the parotid].
    HNO, 1990, Volume: 38, Issue:1

    Topics: Aged; Aprotinin; Chronic Disease; Diagnosis, Differential; Drug Therapy, Combination; Facial Paralys

1990
Ofloxacin in lower respiratory tract infections.
    Infection, 1991, Volume: 19 Suppl 7

    Topics: Bacterial Infections; Bronchitis; Chronic Disease; Cross Infection; Drug Administration Schedule; Dr

1991
[Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract].
    Pneumonologia i alergologia polska, 1991, Volume: 59, Issue:1-2

    Topics: Administration, Oral; Adult; Aged; Bronchitis; Chronic Disease; Drug Resistance, Microbial; Enteroco

1991
Bronchial penetration of ofloxacin after single and multiple oral dosage.
    The Journal of antimicrobial chemotherapy, 1991, Volume: 27, Issue:3

    Topics: Administration, Oral; Adult; Bronchi; Bronchitis; Chronic Disease; Drug Administration Schedule; Fem

1991
Efficacy of oral administration of ofloxacin in lower respiratory tract infections in aged patients with chronic lung disease.
    Chemotherapy, 1991, Volume: 37 Suppl 1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Chronic Disease; Fe

1991
[Urogenital chlamydiosis].
    Fel'dsher i akusherka, 1990, Volume: 55, Issue:9

    Topics: Adult; Chlamydia Infections; Chronic Disease; Diagnosis, Differential; Female; Female Urogenital Dis

1990
Successful treatment of chronic Salmonella excretor with ofloxacin.
    Lancet (London, England), 1986, May-24, Volume: 1, Issue:8491

    Topics: Adult; Anti-Infective Agents; Carrier State; Chronic Disease; Humans; Male; Ofloxacin; Oxazines; Sal

1986
[New oral quinolone compounds in chronic bronchitis].
    Infection, 1986, Volume: 14 Suppl 1

    Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr

1986
[The role of ofloxacin (Tarivid) therapy in respiratory and urinary tract infections].
    Mikrobiyoloji bulteni, 1987, Volume: 21, Issue:3

    Topics: Acute Disease; Chronic Disease; Escherichia coli; Humans; Klebsiella; Ofloxacin; Proteus; Pseudomona

1987
[Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences].
    Infection, 1986, Volume: 14 Suppl 1

    Topics: Acute Disease; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chronic Disease; Humans; Oflox

1986
Clinical evaluation of ofloxacin in lower respiratory tract infections.
    Infection, 1986, Volume: 14 Suppl 4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Chronic Disease; Female; Humans;

1986
Ofloxacin in oral chemotherapy of acute and chronic otitis media.
    Infection, 1986, Volume: 14 Suppl 4

    Topics: Acute Disease; Anti-Bacterial Agents; Chronic Disease; Ear, Middle; Humans; Ofloxacin; Otitis Media;

1986
[In vitro antibacterial activity and pharmacokinetics of ofloxacin in chronic respiratory tract infections].
    The Japanese journal of antibiotics, 1987, Volume: 40, Issue:2

    Topics: Anti-Bacterial Agents; Bacteria; Bronchitis; Chronic Disease; Drug Resistance, Microbial; Humans; Of

1987
Ofloxacin treatment in the management of chronic osteitis.
    Drugs, 1987, Volume: 34 Suppl 1

    Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Chronic Disease; Female; Humans; Male; Microbial Sensi

1987